Tailoring Biologic Care for Medicare Patients With Plaque Psoriasis

In this Expert Therapeutic Update Session, Scott Gottlieb, MD, discusses ILUMYA® for Medicare patients living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

The presentation focuses on the practical access considerations that often shape biologic selection in older patients, including Medicare Part B coverage, health care provider administration, and the option to use either buy and bill in the office or an alternate site of care. Dr Gottlieb also reviews clinical data from the reSURFACE trials, including long-term efficacy and safety findings, with attention to outcomes in patients aged 65 years and older.

For clinicians managing plaque psoriasis in Medicare populations, the session offers a thorough look at how coverage, administration, adherence, and safety considerations can all factor into treatment decisions.